Journal Home Online First Current Issue Archive For Authors Journal Information 中文版

2019, Volume 13, Issue 2

Abstract

Keywords

Related Research

Back to Top

Frontiers of Medicine >> 2019, Volume 13, Issue 2 doi: 10.1007/s11684-018-0634-z

Clinical characteristics in lymphangioleiomyomatosis-related pulmonary hypertension: an observation on 50 patients

. Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;.. Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China

Accepted: 2018-04-18 Available online: 2018-04-18
HTML23 PDF 1 Collect 0

Next Previous

Abstract

Lymphangioleiomyomatosis (LAM) is a rare diffuse cystic lung disease. Knowledge on LAM-related pulmonary hypertension (PH) is limited. This study aimed to analyze the clinical characteristics of LAM with elevated pulmonary artery pressure (PAP) and evaluate the potential efficacy of sirolimus. The study involved 50 LAM patients who underwent echocardiography. According to the tricuspid regurgitation velocity (TRV), these patients were divided into the TRV≤2.8 m/s group and TRV>2.8 m/s group. Both groups comprised 25 females with an average age of 38.6±8.1 and 41.5±8.9 years. In the TRV>2.8 m/s group, the estimated systolic PAP (SPAP) was significantly elevated (52.08±12.45 mmHg vs. 30.24±5.25mmHg, <0.01). Linear analysis showed that SPAP was correlated with forced expiratory volume in 1 s (FEV ), diffusing capacity of the lungs for carbon monoxide, alveolar arterial oxygen gradient (P O ), and 6 min walking distance ( = −0.392, −0.351, 0.450, and −0.591, respectively; <0.05), in which P O was a risk factor for SPAP elevation ( = 0.064, OR= 1.066, <0.05). Moreover, in 10 patients who received sirolimus therapy, SPAP decreased from 57.0±12.6 mmHg to 35.2±11.1 mmHg. The study showed that LAM patients with PH exhibit poor pulmonary function and hypoxemia and may benefit from sirolimus treatment.

Related Research